By Josh Beckerman
Bright Green shares were recently up 43% to 27 cents Thursday after the company received final approval for “unique licensing” for certain drugs from the New Mexico Board of Pharmacy and U.S. Drug Enforcement Administration.
The licensing allows Bright Green to register, license and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients for research, production and manufacturing purposes, the company said.
Write to Josh Beckerman at josh.beckerman@wsj.com
Read the full article here
